ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY A. Maiolino; P. Moreau; M. Dimopoulos; J. Mikhael; K. Yong; M. Capra; T. Facon; R. Hajek; I. Spicka; M. Risse; G. Asset; S. Macé; T. Martin;

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study E. Terpos; A. Symeonidis; S. Delimpasi; E. Zamagni; E. Katodritou; E. Rivolti; M. Kyrtsonis; D. Fotiou; N. Kanellias; M. Migkou; M. Roussou; M. Gavriatopoulou; E. Hatjiharissi; M. Cavo; M. Dimopoulos;

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study M. Turgut; P. Moreau; M. Dimopoulos; J. Mikhael; K. Yong; M. Capra; T. Facon; R. Hajek; I. Spicka; M. Risse; G. Asset; S. Macé; T. Martin;